Stabilis

Cefazolin sodium



Nombre comercial

Acef	Brasil, Marruecos
Ancef	Ecuador, Estados Unidos de América, Grecia
Biofazolin	Polonia
Cecan	Marruecos
Cefacidal	Colombia, Marruecos, Países Bajos
Cefadin	Arabia Saudita, India
Cromezin	Italia

Estabilidad en solucion

		33 mg/ml	2-8°C		2			4922
		400 mg/ml	-20°C		182			581
		10 mg/ml	2-8°C		28			1452
		10 mg/ml	25°C		48			418
		10 mg/ml	25°C	?	7			1452
		400 mg/ml	-20°C		182			581
		10 mg/ml	25°C		48			418
		400 mg/ml	-20°C		182			581
		5 mg/ml	-20°C		182			581
	Phenol 0,04%	33 mg/ml	2-8°C		2			4922
PVC		73,2 mg/ml	-20°C		30			440
PVC		10 mg/ml	-20°C		48			582
PVC		20 mg/ml	-20°C		30			573
PVC		20 mg/ml	5°C		30			3230
PVC		40 mg/ml	5°C		30			3230
PVC		10 mg/ml	-20°C		48			582
PVC		10 mg/ml	4°C		30			656

PVC		20 mg/ml	-20°C		30				576
PVC		20 mg/ml	-20°C		30				573
PVC		20 mg/ml	5°C		30				3230
PVC		40 mg/ml	5°C		30				3230
PVC	Δ® P1 ◆1.5	0,5 mg/ml	25°C	?	8				2372
PVC	Δ® P1 ◆1.5	0,5 mg/ml	37°C	?	24				2372
PVC	Δ® P1 ◆1.5	0,5 mg/ml	4°C	?	14				2372
PVC	Δ® P1 ◆4.25	0,5 mg/ml	25°C	?	8				2372
PVC	Δ® P1 ◆4.25	0,5 mg/ml	37°C	?	24				2372
PVC	Δ® P1 ◆4.25	0,5 mg/ml	4°C	?	14				2372
PVC	Δ® P2 ◆1.5	0,333 mg/ml	25°C	?	11				1979
PVC	Δ® P2 ◆1.5	0,333 mg/ml	37°C	?	24				1979
PVC	Δ® P2 ◆1.5	0,333 mg/ml	4°C	?	20				1979
PVC	Δ® P2 ◆1.5	0,333 mg/ml	4°C	?	20				1979
PVC	EXTRANEAL	0,5 mg/ml	25°C	?	7				1805
PVC	EXTRANEAL	0,5 mg/ml	25°C		7				3888
PVC	EXTRANEAL	0,5 mg/ml	37°C	?	24				1805
PVC	EXTRANEAL	0,5 mg/ml	37°C		24				3888
PVC	EXTRANEAL	0,5 mg/ml	4°C	?	30				1805
PVC	EXTRANEAL	0,5 mg/ml	4°C		14				3888
POF		10 mg/ml	2-8°C		28				1452
POF		10 mg/ml	25°C	?	7				1452
EVA		10 mg/ml	23°C		5				1840
EVA		10 mg/ml	4°C		30				1840
PP		100 mg/ml	5°C		30				3230
PP		200 mg/ml	5°C		30				3230
PP		33 mg/ml	2-8°C		7				4922
PP		333 mg/ml	-20°C		270				574
PP		125 mg/ml	20-25°C		24				4634
PP		50 mg/ml	25°C	?	7				1814
PP		50 mg/ml	5°C	?	22				1814
PP		125 mg/ml	20-25°C		24				4634
PP	Phenol 0.04%	33 mg/ml	2-8°C		7				4922

PI	▲	12,5 mg/ml	35°C	?	12	✓			4247
PI	▲	12,5 mg/ml	4°C	?	72	✓			4247
PI	▲	25 mg/ml	35°C	?	12	✓			4247
PI	▲	25 mg/ml	4°C	?	72	✓			4247
PI	▲	5 & 40 mg/ml	25°C	?	24	✓			604
PI	▲	5 & 40 mg/ml	4°C	☀	10	◑			604
PI	◆	12,5 mg/ml	35°C	?	12	✓			4247
PI	◆	12,5 mg/ml	4°C	?	72	✓			4247
PI	◆	25 mg/ml	35°C	?	12	✓			4247
PI	◆	25 mg/ml	4°C	?	72	✓			4247
PI	◆	5 & 40 mg/ml	25°C	?	24	✓			604
PI	◆	5 & 40 mg/ml	4°C	☀	10	◑			604

Estabilidad en mezcla

	▲	10 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8 ✓	280
	▲	10 mg/ml	25°C	☀	Clindamycin phosphate : 9 mg/ml Gentamicin sulfate : 0,8 mg/ml	12 ✓	695
	▲	10 mg/ml	25°C	☀	Clindamycin phosphate : 9 mg/ml	48 ✓	418
	▲	20 mg/ml	25°C		Ranitidine hydrochloride : 0,5 mg/ml	4 ✓	2355
	◆	10 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8 ✓	280
	◆	5 mg/ml	25°C		Magnesium sulfate : 10 & 20 mg/ml	20 ✓	630
	◆	10 mg/ml	25°C	☀	Clindamycin phosphate : 9 mg/ml Gentamicin sulfate : 0,8 mg/ml	1 ✓	695
	◆	10 mg/ml	25°C	☀	Clindamycin phosphate : 9 mg/ml	48 ✓	418
	◆	10 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4 ✓	2214
	RL	10 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8 ✓	280
	0.45	10 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8 ✓	280
	∅	10 mg/ml	25°C		Metronidazole : 5 mg/ml	7 ◑	631
	∅	10 mg/ml	5°C		Metronidazole : 5 mg/ml	12 ◑	631
	∅	10 mg/ml	8°C		Metronidazole : 5 mg/ml	3 ◑	671
PVC	▲	5 & 20 mg/ml	23°C-25°C		Aztreonam : 10 & 20 mg/ml	48 ✓	426
PVC	▲	5 & 20 mg/ml	4°C-5°C		Aztreonam : 10 & 20 mg/ml	7 ◑	426

PVC		5 & 20 mg/ml	23°C-25°C		Aztreonam : 10 & 20 mg/ml	48	426
PVC		5 mg/ml	4°C	?	Tenoxicam : 0,2 mg/ml	72	1951
PVC		5 & 20 mg/ml	4°C-5°C		Aztreonam : 10 & 20 mg/ml	7	426
PVC	EXTRANEAL	0,5 mg/ml	25°C		Ceftazidime : 0,5 mg/ml	2	3888
PVC	EXTRANEAL	0,5 mg/ml	25°C		Gentamicin sulfate : 0,02 mg/ml	4	3888
PVC	EXTRANEAL	0,125 mg/ml	25°C	?	Ceftazidime : 0,125 mg/ml	24	3651
PVC	EXTRANEAL	0,5 mg/ml	37°C		Ceftazidime : 0,5 mg/ml	24	3888
PVC	EXTRANEAL	0,5 mg/ml	37°C		Gentamicin sulfate : 0,02 mg/ml	24	3888
PVC	EXTRANEAL	0,125 mg/ml	37°C	?	Ceftazidime : 0,125 mg/ml	24	3651
PVC	EXTRANEAL	0,125 mg/ml	4°C		Ceftazidime : 0,125 mg/ml	7	3651
PVC	EXTRANEAL	0,5 mg/ml	4°C		Ceftazidime : 0,5 mg/ml	14	3888
PVC	EXTRANEAL	0,5 mg/ml	4°C		Gentamicin sulfate : 0,02 mg/ml	14	3888
POF		10 mg/ml	23°C		Linezolid : 2 mg/ml	3	1659
POF		10 mg/ml	4°C		Linezolid : 2 mg/ml	7	1659

Factores que influyen sobre la estabilidad

	[400 mg / ml]				501 1371
					301
	37°C				3651
	37°C				4634

Compatibilidades

		Cefazolin sodium : 0,1 mg/ml	0.225 3.75	4693
		Cefazolin sodium : 20 mg/ml Aciclovir sodium : 5 mg/ml		336
		Cefazolin sodium : 20 mg/ml Alfentanil hydrochloride : 500 µg/ml		3380
		Cefazolin sodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
		Cefazolin sodium : 100 mg/ml Alprostadil : 15 µg/ml		3201
		Cefazolin sodium : 20 mg/ml Amifostine : 10 mg/ml		3

		Cefazolin sodium : 20 mg/ml Amifostine : 10 mg/ml		3
		Cefazolin sodium : 20 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Cefazolin sodium		4966
		Cefazolin sodium Amikacin sulfate		3549
		Cefazolin sodium : 40 mg/ml Amiodarone hydrochloride : 3 mg/ml		4698
		Cefazolin sodium : 400 mg/ml		501
		Cefazolin sodium		4966
		Cefazolin sodium : 100 mg/ml	RL	4603
		Cefazolin sodium : 10 mg/ml		4440
		Cefazolin sodium : 20 mg/ml		1415
		Cefazolin sodium : 20 mg/ml		301
		Cefazolin sodium : 10 mg/ml		1055
		Cefazolin sodium : 225 mg/ml		999
		Cefazolin sodium : 400 mg/ml		1371
		Cefazolin sodium : 20 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Cefazolin sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Cefazolin sodium : 20 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Cefazolin sodium : 20 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Cefazolin sodium : 10 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Cefazolin sodium : 5 & 20 mg/ml Aztreonam : 10 & 20 mg/ml		426
		Cefazolin sodium : 20 mg/ml Aztreonam : 40 mg/ml		99
		Cefazolin sodium : 5 & 20 mg/ml Aztreonam : 10 & 20 mg/ml		426
		Cefazolin sodium : 20 mg/ml Bivalirudin : 5 mg/ml		1713
		Cefazolin sodium Bleomycin sulfate		4154
		Cefazolin sodium : 100 mg/ml Caffeine : 10 mg/ml	∅	3964
		Cefazolin sodium Calcium gluconate		3644
		Cefazolin sodium : 100 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Cefazolin sodium : 20 mg/ml Caspofungin acetate : 0,7 mg/ml		2247

		Cefazolin sodium : 20 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Cefazolin sodium : 20 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Cefazolin sodium : 10 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
		Cefazolin sodium : 10 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Cefazolin sodium : 10 mg/ml Cefpirome sulfate : 50 mg/ml	0.45	280
		Cefazolin sodium : 10 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Cefazolin sodium : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Cefazolin sodium : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Cefazolin sodium : 1 mg/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml		1201
24		Cefazolin sodium : 10 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Cefazolin sodium : 1 mg/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml		1201
		Cefazolin sodium : 20 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Cefazolin sodium : 20 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
		Cefazolin sodium : 10 mg/ml Clindamycin phosphate : 9 mg/ml		418
		Cefazolin sodium Clindamycin phosphate		3526
		Cefazolin sodium : 10 mg/ml Clindamycin phosphate : 9 mg/ml		418
		Cefazolin sodium Clindamycin phosphate		3526
		Cefazolin sodium : 10 mg/ml Cloxacillin sodium : 100 mg/ml		3012
1		Cefazolin sodium : 41.6 mg/ml Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml		4254
		Cefazolin sodium Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Cefazolin sodium : 20 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Cefazolin sodium : 200 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Cefazolin sodium : 20 & 200 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Cefazolin sodium Dimenhydrinate		2087
		Cefazolin sodium : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Cefazolin sodium : 100 mg/ml Doxapram hydrochloride : 2 mg/ml		1802

	✓	Cefazolin sodium : 20 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml	◆	251
	✓	Cefazolin sodium : 20 mg/ml Enalaprilate : 0.05 mg/ml	▲	1315
?	✗	Cefazolin sodium Erythromycin lactobionate		3674
1	✗	Cefazolin sodium : 220 mg/ml Erythromycin lactobionate : 20 mg/ml		805
	✓	Cefazolin sodium : 10 mg/ml Esmolol hydrochloride : 10 mg/ml	◆	384
	✓	Cefazolin sodium : 20 mg/ml Etoposide phosphate : 5 mg/ml	◆	1410
	✓	Cefazolin sodium : 20 mg/ml Famotidine	◆	397
	✓	Cefazolin sodium : 20 mg/ml Famotidine : 2 mg/ml	▲	215
	✓	Cefazolin sodium : 20 mg/ml Fenoldopam mesylate : 80 µg/ml	▲	1803
	✓	Cefazolin sodium : 20 mg/ml Fentanyl citrate : 50 µg/ml	◆	63
	✓	Cefazolin sodium : 20 mg/ml Fentanyl citrate : 50 µg/ml		3380
	✓	Cefazolin sodium : 20 mg/ml Filgrastim : 30 µg/ml	◆	244
	✓	Cefazolin sodium : 40 mg/ml Fluconazole : 2 mg/ml	▲	496
	✓	Cefazolin sodium : 20 mg/ml Fluconazole : 2 mg/ml	∅	256
	✓	Cefazolin sodium : 20 mg/ml Fludarabine phosphate : 1 mg/ml	◆	492
	✓	Cefazolin sodium : 40 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
	✓	Cefazolin sodium : 20 mg/ml Fosfomycin : 30 mg/ml	▲	4055
	✓	Cefazolin sodium : 20 mg/ml Fosfomycin : 30 mg/ml	◆	4055
	✓	Cefazolin sodium : 100 mg/ml Gallium nitrate : 1 mg/ml	▲	91
	✓	Cefazolin sodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml	▲	1423
?	✗	Cefazolin sodium Gentamicin sulfate		3520
?	✗	Cefazolin sodium Gentamicin sulfate		3643
	✓	Cefazolin sodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml	◆	182
	✓	Cefazolin sodium : 20 mg/ml Heparin sodium : 50 UI/ml	∅	317
	✓	Cefazolin sodium : 10 mg/ml Heparin sodium : 10 & 5000 UI/ml	▲	2037
	✓	Cefazolin sodium : 0.333 mg/ml Heparin sodium : 0.667 UI/ml	Δ® P2 ◆ 1.5	1979

		Cefazolin sodium : 20 mg/ml Hetastarch : 60 mg/ml		472
		Cefazolin sodium : 20 mg/ml Hetastarch : 60 mg/ml		465
		Cefazolin sodium : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Cefazolin sodium : >200 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml		226
		Cefazolin sodium : 20 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml		226
		Cefazolin sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Cefazolin sodium : 20 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Cefazolin sodium : 20 mg/ml Insulin : 0.2 UI/ml		129
		Cefazolin sodium : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Cefazolin sodium : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Cefazolin sodium : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Cefazolin sodium : 10 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Cefazolin sodium : 20 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Cefazolin sodium : 41.6 mg/ml Levetiracetam : 5.21 & 20.83 mg/ml		4254
		Cefazolin sodium : 41.6 mg/ml Levetiracetam : 5.21 & 20.83 mg/ml		4254
		Cefazolin sodium : 41.6 mg/ml Levofloxacine : 5 mg/ml		4254
		Cefazolin sodium Lidocaine hydrochloride : 5 mg/ml		4966
		Cefazolin sodium Lidocaine hydrochloride		499
		Cefazolin sodium : 20 mg/ml Linezolid : 2 mg/ml		1925
		Cefazolin sodium : 10 mg/ml Linezolid : 2 mg/ml		1659
		Cefazolin sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Cefazolin sodium : 5 mg/ml Magnesium sulfate : 10 & 20 mg/ml		630
		Cefazolin sodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
		Cefazolin sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
		Cefazolin sodium : 10 mg/ml Metronidazole : 5 mg/ml		631
		Cefazolin sodium Metronidazole		3594

		Cefazolin sodium : 10 mg/ml Metronidazole : 5 mg/ml	∅	1035
		Cefazolin sodium : 20 mg/ml Midazolam hydrochloride : 1 mg/ml	◆	176
		Cefazolin sodium : 20 mg/ml Morphine sulfate : 1 mg/ml	◆	405
		Cefazolin sodium N-acetylcysteine : 200 mg/ml	∅	3766
		Cefazolin sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Cefazolin sodium : 41.6 mg/ml Nefopam : 0.16 mg/ml	▲	4254
		Cefazolin sodium : 41.6 mg/ml Nefopam : 0.16 mg/ml	◆	4254
		Cefazolin sodium : 20 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	▲	1490
		Cefazolin sodium : 20 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	◆	1490
		Cefazolin sodium : 20 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
		Cefazolin sodium : 20 mg/ml Palonosetron hydrochloride : 50 µg/ml	◆	2214
		Cefazolin sodium : 10 mg/ml Pancuronium bromide : 0.05 mg/ml	◆	402
		Cefazolin sodium : 41.6 mg/ml Pantoprazole sodium : 4 mg/ml	◆	4254
		Cefazolin sodium Pantoprazole sodium		2090
		Cefazolin sodium : 20 >> 40 mg/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml	▲	1902
		Cefazolin sodium : 41.6 mg/ml Pantoprazole sodium : 4 mg/ml	▲	4254
		Cefazolin sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Cefazolin sodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
		Cefazolin sodium : 20 mg/ml Pentamidine isetionate : 3 mg/ml	◆	275
		Cefazolin sodium : 10 mg/ml Pethidine hydrochloride : 0,5 mg/ml	◆	111
		Cefazolin sodium : 20 mg/ml Piritramide : 7.5 mg/ml		3380
		Cefazolin sodium : 20 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
		Cefazolin sodium : 10 mg/ml Promethazine hydrochloride : 25 mg/ml	◆	103
		Cefazolin sodium : 20 mg/ml Propofol : 10 mg/ml	∅	300
		Cefazolin sodium Protamine sulfate		2071
		Cefazolin sodium : 20 mg/ml Ranitidine hydrochloride : 1 mg/ml	▲	2355

		Cefazolin sodium : 20 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
		Cefazolin sodium Rocuronium bromide		3564
		Cefazolin sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Cefazolin sodium : 20 mg/ml Sargramostim : 10 µg/ml	▲	335
		Cefazolin sodium : 20 mg/ml Sufentanil citrate : 0.005 mg/ml		3380
		Cefazolin sodium : 250 mg/ml Sugammadex : 100 mg/ml	∅	3372
		Cefazolin sodium : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml	▲	4801
		Cefazolin sodium : 40 mg/ml Tacrolimus : 1000 µg/ml	▲	479
		Cefazolin sodium : 20 mg/ml Tedizolid phosphate : 0.8 mg/ml	▲	3827
		Cefazolin sodium : 20 mg/ml Teniposide : 0.1 mg/ml	◆	905
		Cefazolin sodium : 5 mg/ml Tenoxicam : 0,2 mg/ml	◆	1951
		Cefazolin sodium : 20 mg/ml Theophylline : 4 mg/ml	∅	317
		Cefazolin sodium : 100 mg/ml Thiopental sodium : 25 mg/ml	▲	3767
		Cefazolin sodium : 20 mg/ml Thiotepa : 1 mg/ml	◆	249
		Cefazolin sodium : 10 >> 200 mg/ml Vancomycin hydrochloride : 20 mg/ml	◆	1674
		Cefazolin sodium : 1 ; 10 & 200 mg/ml Vancomycin hydrochloride : 2 mg/ml	◆	1674
		Cefazolin sodium : 1 mg/ml Vancomycin hydrochloride : 20 mg/ml	◆	1674
		Cefazolin sodium : 50 mg/ml Vancomycin hydrochloride : 2 mg/ml	◆	1674
		Cefazolin sodium : 10 mg/ml Vecuronium bromide : 0.1 mg/ml	◆	402
		Cefazolin sodium : 2 mg/ml Verapamil hydrochloride : 0.08 mg/ml	▲	1057
		Cefazolin sodium : 2 mg/ml Verapamil hydrochloride : 0.08 mg/ml	◆	1057
		Cefazolin sodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84
		Cefazolin sodium : 20 mg/ml Warfarin sodium : 2 mg/ml	◆	315

método de inyección

Bibliografía

	Tipo	Publicación
3	periódico	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	periódico	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	periódico	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	periódico	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	periódico	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	periódico	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	periódico	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
103	periódico	Erickson SH, Ulici D. Incompatibility of cefotetan disodium and promethazine hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 1347.
111	periódico	Lee DKT, Wong CY, Wang DP. Stability of cefazolin sodium and meperidine hydrochloride. Am J Health-Syst Pharm 1996 ; 53: 1608,1610.
129	periódico	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
169	periódico	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	periódico	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.

198	periódico	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	periódico	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
226	periódico	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.
244	periódico	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	periódico	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
256	periódico	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
275	periódico	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
280	periódico	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
299	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	periódico	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	periódico	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	periódico	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	periódico	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	periódico	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.

335	periódico	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	periódico	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
384	periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	periódico	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	periódico	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
402	periódico	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
405	periódico	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
418	periódico	Bosso JA, Townsend RJ. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm 1985 ; 42: 2211-2214.
426	periódico	Riley CM, James MJ. Stability of intravenous admixtures containing aztreonam and cefazolin. Am J Hosp Pharm 1986 ; 43: 925-927.
440	periódico	Stiles ML, Tu YH, Allen LV. Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm 1989 ; 46: 1408-1412.
465	periódico	Wohlford JG, Wright JC, Wilson MR. More information on the visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1990 ; 47: 297-298.
472	periódico	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
479	periódico	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	periódico	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.

492	periódico	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	periódico	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
499	periódico	Rockwell K, Burch K. Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient. Hosp Pharm 1991 ; 26: 634-635.
501	periódico	Senholzi CS, Kerns MP. Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. Am J Hosp Pharm 1985 ; 42: 129-130.
573	periódico	Dinel BA, Ayotte DL, Behme RJ, Black BL, Whitby JL. Stability of antibiotic admixtures frozen in minibags. Drug Intell Clin Pharm 1977 ; 11: 542-548.
574	periódico	Kleinberg ML, Stauffer GL, Prior RB, Latiolais CJ. Stability of antibiotics frozen and stored in disposable hypodermic syringes. Am J Hosp Pharm 1980 ; 37: 1087-1088.
576	periódico	Holmes CJ, Ausman RK, Walter CW, Kundsin RB. Activity of antibiotic admixtures subjected to different freeze-thaw treatments. Drug Intell Clin Pharm 1980 ; 14: 353-357.
581	periódico	Carone SM, Bornstein M, Coleman DL, Thomas PN, Boylan JC. Stability of frozen solutions of cefazolin sodium. Am J Hosp Pharm 1976 ; 33: 639-641.
582	periódico	Tomecko GW, Kleinberg ML, Latiolais CL, Proior RB, Pesko LJ, Jones BC. Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation. Am J Hosp Pharm 1980 ; 37: 211-215.
604	Laboratorio	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
630	periódico	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.
631	periódico	Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148.
656	periódico	Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J. Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions. J Clin Pharm Ther 1996 ; 21: 185-189.
671	periódico	Rivers TE, McBride HA, Trang JM. Stability of cefazolin sodium and metronidazole at 8°C for use as an IV admixture. J Parenter Sci Technol 1993 ; 47: 135-137.
695	periódico	Zbrozek AS, Marble DA, Bosso JA. Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions. Drug Intell Clin Pharm 1988 ; 22: 873-875.
805	periódico	Oskroba DM, Leissing NC, Trissel LA. An automated process for determining the physical compatibility of drugs. Hosp Pharm 1997 ; 32: 1013-1020.

905	periódico	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	periódico	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	periódico	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	periódico	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	periódico	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1055	periódico	Faragos S. Compatibility of antibiotics and other drugs in total parenteral nutrition solutions. Can J Hosp Pharm 1983 ; 36: 43-52.
1057	periódico	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1201	periódico	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1371	periódico	Bornstein M, Templeton RJ. Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. Am J Hosp Pharm 1985 ; 42: 2436.
1410	periódico	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	periódico	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	periódico	Muller HJ, Howe K, Frank C, Haker I. Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1490	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625	periódico	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.

1659	periódico	Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics. J Am Pharm Assoc 2000 ; 40: 509-514.
1674	periódico	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	periódico	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	periódico	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	periódico	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	periódico	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1802	periódico	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	periódico	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1805	periódico	Lin YF, Wu CC, Lin SH, Wang DP, Wang CN. Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution. Am J Health-Syst Pharm 2002 ; 59: 2362-2364.
1814	periódico	Gupta VD. Chemical stability of cefazolin sodium after reconstituting in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2003 ; 7, 2: 152-154.
1840	periódico	Xu QA, Trissel LA, Saenz CA et al. Stability of three cephalosporin antibiotics in autodose infusion system bags. J Am Pharm Assoc 2002 ; 42: 428-431.
1902	periódico	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	periódico	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1951	periódico	Wang DP, Lee D, Wang CN. Stability of sodium cefazolin and tenoxicam in 5% dextrose. Chin Pharm J 2001 ; 53: 185-189.
1953	periódico	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1979	periódico	Wu CC, Wang DP, Wong CY, Lin YF. Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions. Am J Health-Syst Pharm 2002 ; 59: 1537-1538.

1982	periódico	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2037	periódico	Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/antibiotic solutions ... J Antimicrob Chemother 2005 ; 56: 951-953.
2071	periódico	Ng HP, Koh KF. Precipitation of protamine by cefazolin. Anesth Analg 2002 ; 95: 785.
2087	periódico	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	periódico	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	periódico	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2214	periódico	Ben M, Trusley C,Kupiec T.C, Trissel L.A. Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 6: 520-524.
2233	periódico	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	periódico	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2355	periódico	Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M. Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium nd cephalotin sodium during simulated Y-site administration. Int J Pharm Compound 2000 ; 4, 2: 150-153.
2372	periódico	Nahata MC, Ahalt PA. Stability of cefazolin sodium in peritoneal dialysis solutions Am J Hosp Pharm 1991 ; 48: 291 - 292.
3012	periódico	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3201	periódico	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216	periódico	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3230	periódico	Donnelly RF. Stability of Cefazolin Sodium in Polypropylene Syringes and Polyvinylchloride Minibags Can J Hosp Pharm 2011 ; 64, 4: 241-245.
3372	periódico	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.

3380	periódico	Eckle V-S, Heim E, Hahn M, Grasshoff C. Incompatibility of Piritramide with Cephalosporins. Ann Pharmacotherapy 2013 ;47:426-427.
3408	periódico	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Laboratorio	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3526	Laboratorio	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3549	Laboratorio	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3564	Laboratorio	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3594	Laboratorio	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Laboratorio	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3644	Laboratorio	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3651	periódico	Patel R.P, Shastri M.D, Bakkari M, Wanandy T, Jose M.D. Stability of the Combination of Ceftazidime and Cephazolin in Icodextrin or pH Neutral Peritoneal Dialysis Solution. Perit Dial Int 2014 ; 34:212-218
3674	Laboratorio	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	periódico	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	periódico	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	periódico	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	póster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3888	periódico	Ranganathan D, Naicker S,. Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). Perit Dial Int 2016 ; 36:421-426.
3964	periódico	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.

4055	periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	periódico	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4154	Laboratorio	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4247	periódico	Patel R, Jacob J, Sedeeq M, Ming L.C, Wanandy T, Zaidi S.T.R, Peterson G.M. Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices. Clin Ther 2018 ;40,4:664-667
4254	periódico	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	periódico	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4440	periódico	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4528	periódico	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	periódico	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	periódico	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4654	póster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4693	periódico	Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L. Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection. Drug Design Dev Ther 2022 ;16:1433-1440.
4698	periódico	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022 ; 7(1): 20220002
4742	periódico	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	periódico	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4922	periódico	Wanandy T, Handley SA, Le TTA, Lau WY, Turner ME, Wiese MD. Stability of Antibiotics for Use in the Testing of Immediate Drug Allergy Reactions. J Allergy Clin Immunol Pract 2024 13, 2: 343-352.

4966	Laboratorio	CEFAZOLINE PANPHARMA 1 g, poudre pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. PANPHARMA 2023

Stabilis

Cefazolin sodium



La estabilidad de las preparaciones farmacéuticas

	16,6 mg Kefzol® (Eli Lilly)	NaCl 0.9% >> 5 ml	4°C		7			2505
	16,6 mg Kefzol® (Eli Lilly)	Tampón de acetato pH 4,5 >> 5 ml	4°C		7			2505
	16,6 mg Kefzol® (Eli Lilly)	Tampón de acetato pH 5,7 >> 5 ml	4°C		7			2505
	500 mg ® = Cefazolin panpharma	NaCl 0.45% >> 10 mL	4°C		30			2707
	500 mg ® = Cefazolin panpharma	Tiomersal 0,5 mg Glicerina 100 mg Agua para inyección >> 10 ml	4°C		30			2707
?	200mg Cefazoline	Agua para inyección 1ml Tears Naturale® 3ml	2-8°C		28			3155
?	200mg Cefazoline	Agua para inyección 1ml Natear® 3ml	2-8°C		28			3155
?	50 mg ® = (Biosyntez)	NaCl 0.9% >> 10 ml	2-8°C		14			4894
?	50 mg ® = Biosintez	NaCl 0.9% >> 10 ml	23-27°C		7			4894
?	500 mg Biofazolin®	Tampón citrato pH 6.27 - 161 mOsmol/L	4°C		30			3291
?	500 mg Biofazolin®	Tampón citrato pH 6.27 - 161 mOsmol/L Borato fenilmercúrico 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C		30			3291
?	500 mg Biofazolin®	Tampón citrato pH 6,22 - 308 mOsmol/L Alcohol polivinílico ŋ = 42.3 mPas pH 4.48 - 4.95 g Borato fenilmercúrico 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C		30			3291
?	500 mg Biofazolin®	Tampón citrato pH 6,22 - 308 mOsmol/L Alcohol polivinílico ŋ = 42.3 mPas pH 4.48 - 4.90 g	4°C		30			3291
?	100 mg Biofazolin®	Tampón citrato pH 6,22 - 308 mOsmol/L	4°C		30			3291

?		100 mg Biofazolin®	Tampón citrato pH 6,22 - 308 mOsmol/L Borato fenilmercúrico 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C	g	30			3291
?		100 mg Biofazolin®	Tampón citrato pH 6,11 - 581 mOsmol/L Alcohol polivinílico ŋ = 42.3 mPas pH 4.48 - 4.50	4°C	g g	30			3291
?		100 mg Biofazolin®	Tampón citrato pH 6,11 - 581 mOsmol/L Alcohol polivinílico ŋ = 42.3 mPas pH 4.48 - 4.55 Borato fenilmercúrico 0.04% 250 mg Texte introuvable (10553,) 40 mg	4°C	g g	30			3291

Factores que influyen sobre la estabilidad

					3155
		40°C			2868
	25°C				2505 2707
	pH >7				2505

Bibliografía

	Tipo	Publicación
2505	periódico	Ahmed I, Day P. Stability of cefazolin sodium in various artificial tear solutions and aqueous vehicles Am J Hosp Pharm 1987 ; 44: 2287-2290
2707	periódico	How TH, Loo WY, Yow KL, Lim LY, Chan EW, Ho PC, Chan SY. Stability of cefazolin sodium eye drops J Clin Pharm Ther 1998 ; 23, 1: 41-47.
2868	periódico	Kommanaboyina B, Lindauer RF, Rhodes CT, Grady LT. Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution. Int J Pharm Compound 2000 ; 4, 2: 146-149.
3155	periódico	Rojanarata T, Tankul J, Woranaipinich C, Potawanich P, Plianwong S, Sakulma S, Saehuan C. Stability of Fortified Cefazolin Ophthalmic Solutions Prepared in Artificial Tears Containing Surfactant-Based Versus Oxidant-Based Preservatives. J Ocular Pharm Ther 2010 ; 26, 5: 485-490.
3291	periódico	Kodym A, Bilski P, Domanska A, Lukasz Helminiak, Jablonska M, Jachymska A. Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method. Acta Pol Pharm 2012 ; 69, 1: 95-105.
4894	periódico	Valiev A.K, Zdoryk A.A, Georgiyants V.A. Chemical stability of pharmacy-compounded cefazolin sodium eye drops. Pharm Chem J 2015 ; 48, 11: 761-763.

Diccionario

	Antibiótico		Inyectables
	Nombre comercial		Estabilidad en solucion
	Envase		Molécula
	Concentración		Temperatura
	Conservación		Duración de la estabilidad
	biosimilar		datos contradictorios
	Bibliografía		Vidrio
	Agua para preparación inyectable		A cubierto de la luz
	Día		Cloruro de sodio 0,9%
	Luz		Hora
	No precisada		Glucosa 5%
	NaCl 0.9% + fenol 0.4%	PVC	Cloruro de polivinilo
Δ® P1 1.5	Dianéal® PD1 1.5% Glucosa (Baxter)	Δ® P1 4.25	Dianéal® PD1 4.25% Glucosa (Baxter)
Δ® P2 1.5	Dianéal® PD2 1.5% Glucosa (Baxter)	EXTRANEAL	Extraneal® (Baxter)
POF	Poliolefina	EVA	Etilén-vinil-acetato
	jeringa polipropileno	P I	Elastómero de poliisopreno
	Estabilidad en mezcla		Solvente
	Molécula	RL	Ringer lactato
0.45	Cloruro de sodio 0,45%	Ø	Ninguno
	Factores que influyen sobre la estabilidad		Provoque
	Precipitación		Nutrición parenteral (libre de lípidos)
	Degradación		Disminución de la estabilidad
	NaCl 0,9% o glucosa 5%		Compatibilidades
	Compatible	0.225 3.75	NaCl 0,225 % + glucosa 3.75 %
	Inestabilidad química		Incompatible
	Precipitación inmediata		Nutrición parenteral (con lípidos)
	Turbidez inmediata		Incompatibilidad no especificada
24	Turbidez en 24 horas	1	Turbidez en una hora
	específico disolvente	1	Precipitación después de 1 hora
	Precipitación después de 4 horas.	2	Precipitación después de 2 horas.

	Cambio de color después de 4 horas.		método de inyección
	Intravenoso		Perfusión intravenosa
	Perfusión continua		Intramuscular
	Intraperitoneal		Bibliografía
	Gotas oculares		La estabilidad de las preparaciones farmacéuticas
	Origine		Excipiente
	Frasco para medicamentos inyectables	?	No precisado
	Polvo		Aumento
	Diccionario		